The effect of urine testing in evaluations of the sensitivity of the Gen-Probe APTIMA® Combo 2 assay on endocervical swabs for Chlamydia trachomatis and Neisseria gonorrhoeae -: The infected patient standard reduces sensitivity of single site evaluation

被引:55
作者
Moncada, J
Schachter, J
Hook, EW
Ferrero, D
Gaydos, C
Quinn, TC
Willis, D
Weissfeld, A
Martin, DH
机构
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Univ Alabama Birmingham, Birmingham, AL USA
[3] San Joaquin Cty Publ Hlth Serv, Stockton, CA USA
[4] Johns Hopkins Univ, Baltimore, MD 21218 USA
[5] Florida Dept Hlth, Jacksonville, FL USA
[6] Microbiol Specialist Inc, Houston, TX USA
[7] Louisiana State Univ, New Orleans, LA USA
关键词
D O I
10.1097/01.OLQ.0000124611.73009.D5
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: The Gen-Probe APTIMA Combo 2 (AC2) assay is a second-generation transcription-mediated amplification assay for the detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). Goal: The goal of this study was to evaluate AC2 performance of endocervical (cx) swabs for the detection of CT and NG using either a specimen or an infected patient standard. Study Design: In a multicenter clinical study, we compared AC2 with Abbott's ligase chain reaction (LCR) and Roche's polymerase chain reaction (PCR; Amplicor or COBAS) for CT, and we compared AC2 with Abbott's LCR and culture for NG. A total of 1569 females were enrolled in the study; we collected cx and first-catch urine (FCU) specimens. Results: CT prevalence was 13.3% for ex specimens and 13.7% for FCU specimens. NG prevalence was 8.7% and 7.9% for cx and FCU specimens, respectively. When based only on cx specimens, AC2, LCR, and PCR sensitivities for CT were 99.4%, 95.6%, and 95.6%, respectively. However, cx sensitivity for CT was reduced to 92.1%, 86.6%, and 87.1% for each respective assay when based on both cx and FCU specimen results (infected patient standard). NG sensitivities for AC2, LCR, and culture based solely on cx specimen results were 99.2%, 96.1%, and 85.9%, respectively. Based on infected patient standard, the sensitivities of each respective assay were 98.5%, 93.9%, and 84.0%. Conclusions: The infected patient standard reduces the sensitivity of the endocervical evaluation because some infected patients are positive only with FCU. The reduction in sensitivity is greater when testing for CT. Specificities improved slightly, because some unique ex positives, initially classified as false-positive were confirmed by a positive FCU result. Sensitivity of AC2 was higher than LCR, PCR, and culture. Specificity was slightly lower, but discrepant analysis (using alternate TMA targets) of apparent AC2 false-positives showed that 75% to 80% were true-positives.
引用
收藏
页码:273 / 277
页数:5
相关论文
共 26 条
[1]   Head-to-head multicenter comparison of DNA probe and nucleic acid amplification tests for Chlamydia trachomatis infection in women performed with an improved reference standard [J].
Black, CM ;
Marrazzo, J ;
Johnson, RE ;
Hook, EW ;
Jones, RB ;
Green, TA ;
Schachter, J ;
Stamm, WE ;
Bolan, G ;
Louis, MES ;
Martin, DH .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (10) :3757-3763
[2]  
BOTT M, 2001, P INT C SEX TRANSM I, P55
[3]  
Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P1
[4]   LIGASE CHAIN-REACTION FOR DETECTION OF NEISSERIA-GONORRHOEAE IN UROGENITAL SWABS [J].
CHING, SF ;
LEE, H ;
HOOK, EW ;
JACOBS, MR ;
ZENILMAN, J .
JOURNAL OF CLINICAL MICROBIOLOGY, 1995, 33 (12) :3111-3114
[5]   Specimen processing and concentration of Chlamydia trachomatis added can influence false-negative rates in the LCx assay but not in the APTIMA combo 2 assay when testing for inhibitors [J].
Chong, S ;
Jang, D ;
Song, X ;
Mahony, J ;
Petrich, A ;
Barriga, P ;
Chernesky, M .
JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (02) :778-782
[6]   COMPARISON OF THE SYVA MICROTRAK ENZYME-IMMUNOASSAY AND GEN-PROBE PACE-2 WITH CELL-CULTURE FOR DIAGNOSIS OF CERVICAL CHLAMYDIA-TRACHOMATIS INFECTION IN A HIGH-PREVALENCE FEMALE-POPULATION [J].
CLARKE, LM ;
SIERRA, MF ;
DAIDONE, BJ ;
LOPEZ, N ;
COVINO, JM ;
MCCORMACK, WM .
JOURNAL OF CLINICAL MICROBIOLOGY, 1993, 31 (04) :968-971
[7]   Detection of Chlamydia trachomatis by the Gen-Probe AMPLIFIED Chlamydia Trachomatis Assay (AMP CT) in urine specimens from men and women and endocervical specimens from women [J].
Crotchfelt, KA ;
Pare, B ;
Gaydos, C ;
Quinn, TC .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (02) :391-394
[8]   Performance of the gen-probe AMPLIFIED Chlamydia trachomatis assay in detecting Chlamydia trachomatis in endocervical and urine specimens from women and urethral and urine specimens from men attending sexually transmitted disease and family planning clinics [J].
Ferrero, DV ;
Meyers, HN ;
Schultz, DE ;
Willis, SA .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (11) :3230-3233
[9]   Performance of the APTIMA Combo 2 assay for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in female urine and endocervical swab specimens [J].
Gaydos, CA ;
Quinn, TC ;
Willis, D ;
Weissfeld, A ;
Hook, EW ;
Martin, DH ;
Ferrero, DV ;
Schachter, J .
JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (01) :304-309
[10]  
Hadgu A, 1997, STAT MED, V16, P1391, DOI 10.1002/(SICI)1097-0258(19970630)16:12<1391::AID-SIM636>3.0.CO